Name | Procaine hydrochloride |
Synonyms | cetain irocaine eugerase ethocaine bernocaine ATOXICAINE chlorocaine Procaine Hcl TIMTEC-BB SBB001081 Procaine hydrochloride 2-(Diethylamino)ethyl 4-aminobenzoate 2-methylpropyl 4-aminobenzoate hydrochloride diethylaminoethanol4-aminobenzoatehydrochloride |
CAS | 51-05-8 |
EINECS | 200-077-2 |
InChI | InChI=1/C13H20N2O2.ClH/c1-4-15(5-2)13(3,17)12(16)10-6-8-11(14)9-7-10;/h6-9,17H,4-5,14H2,1-3H3;1H |
InChIKey | HCBIBCJNVBAKAB-UHFFFAOYSA-N |
Molecular Formula | C13H21ClN2O2 |
Molar Mass | 272.77 |
Density | 1.1761 (rough estimate) |
Melting Point | 155-156°C(lit.) |
Boling Point | 195-196°C 17mm |
Flash Point | 195-196°C/17mm |
Water Solubility | soluble |
Solubility | Solution S is clear (2.2.1) and colourless (2.2.2, Method II). |
Appearance | Crystals or Crystalline Powder |
Color | Colorless to white |
Merck | 14,7757 |
BRN | 3917802 |
Storage Condition | 2-8°C |
Stability | Stable. Incompatible with strong oxidizing agents. |
Sensitive | Air Sensitive |
Refractive Index | 1.5270 (estimate) |
Use | Local anesthetics for infiltration of local anesthesia, nerve block, etc |
In vitro study | Procaine acts primarily by inhibiting the influx of sodium ions through voltage-gated sodium channels on the cell membrane of neurons in peripheral nerves. When the internal flow of sodium ions is interrupted, the action potential cannot occur and the signal transmission is therefore inhibited. The receptor site is considered to be located in the cytoplasmic (internal) portion of the sodium channel. Procaine is also capable of binding to or antagonizing the function of the N-methyl-D-aspartate (NMDA) receptor and the nicotinic acetylcholine receptor and serotonin receptor-ion channel complex. Procaine is an inhibitor of calcium and caffeine-induced calcium release in various types of muscle preparations. 0.5 mM Procaine blockade of sarcoplasmic reticulum in individual lipid bilayers CaProcaine can be used as a DNA demethylating agent with inhibitory effect on the growth of human cancer cells. 0.5 mM Procaine was able to reduce 5-methylcytosine DNA by 40% in MCF-7 breast cancer cell lines. Procaine is also able to bind to CpG-enriched DNA, demethylating densely hypermethylated CpG sequences, resulting in epigenetically silenced genes restoring gene expression. Procaine treatment (0.5 mM) increased the mitotic index of cells in M-phase. Procaine treatment (1 mM) reduced cell proliferation by ~ 40%. Procaine affects the shape and deformability of red blood cells. 45 mM Procaine almost completely prevented the discoid cell-Acanthocyte conversion associated with ATP depletion. Similar concentrations of Procaine normalized ATP-depleted cell stickiness and filterability, but had no effect on cell volume, osmotic fragility, or monovalent cation composition. |
In vivo study | Procaine is a stimulant of the cells of the limbic system. In awake cats, 15 mg/kg Procaine increased cellular activity in the hippocampus ventral amygdala, nucleus accumbens, temporal neocortex, and ventromedial hypothalamus. Procaine promotes the conduction of evoked stimulatory activity from the amygdala to the ventromedial hypothalamus. sup> [8]Procaine affects the frequency and amplitude of rhythmic slowing activity in the hippocampus elicited as a network. Procaine (0.5 microliters, 20% weight/volume) is injected in the ascending system before the suprapillary nucleus, near the medial forebrain bundle or in the medial barrier area, it reduces the amplitude of hippocampal rhythmic slowing activity (RSA) elicited in the form of a reticular, with no effect on frequency. The injection of Procaine in the ascending system preceding the site of reticular stimulation, reaching, and including the suprapapillary nucleus, simultaneously reduced the frequency and amplitude of RSA elicited in the reticular form. In rats, Procaine (80 mg/kg) increased the duration and conduction range of post-epileptiform discharges (ADs) produced by electrical stimulation of the amygdala. Porcaine also increased seizure development (kindling) in rats produced by repeated amygdala stimulation. In adequately stimulated subjects, Procaine may also act as a convulsant. Procaine produced a weak but significant increase in the amplitude of the transcallosal evoked potentials. Procaine affects the production of auditory brainstem responses (ABRs). Procaine (30 microliters of 1% solution) was injected into the oblique body of guinea pigs, affecting many scalp-derived ABR components: N2 was delayed, the duration of P2 was longer, P3 and N3 disappeared, the latency of P4 is shortened, the duration becomes longer, the amplitude is not affected, and N4 is greatly attenuated. Only P1 and N1 were not affected by procaine injection. Procaine increases the therapeutic index of cisplatin by improving the antitumor activity of cisplatin and reduces its nephrotoxicity. In BDF1 mice, the combined administration of cisplatin and Procaine (40 mg/kg) produced 50% of the lethal dose (LD50) and 90% of the lethal dose (LD90) the value is almost 2-fold higher than that of cisplatin alone. The combined administration produced a higher cure rate than cisplatin alone (50% vs. 9%). After 4-7 days of cisplatin alone, increased blood urea nitrogen (BUN) levels were observed, as well as tubular degeneration detected by light microscopy, these phenomena were not observed when the same doses of cisplatin and Procaine were administered in combination. |
Hazard Symbols | T - Toxic |
Risk Codes | R25 - Toxic if swallowed R43 - May cause sensitization by skin contact R36/37/38 - Irritating to eyes, respiratory system and skin. R23/24/25 - Toxic by inhalation, in contact with skin and if swallowed. |
Safety Description | S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S37/39 - Wear suitable gloves and eye/face protection S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
UN IDs | UN 2811 6.1/PG 3 |
WGK Germany | 3 |
RTECS | DG2275000 |
TSCA | Yes |
HS Code | 29242990 |
Hazard Class | 6.1 |
Packing Group | III |
Toxicity | LD50 in mice (mg/kg): 660 ± 60 s.c. (Goldenthal) |
This product is 4-aminobenzoic acid -2-(diethylamino) ethyl ester hydrochloride. The content of C13H20N202 • HC1 shall not be less than 99.0% calculated as dry product.
The melting point of this product (General rule 0612 first method) is 154~157°C.
take 0.40g of this product, Add 10ml of water to dissolve, add 1 drop of Methyl red indicator solution, if it is red, add 0.02 ml of sodium hydroxide titration solution (0.20 mol/L), and the strain is orange.
take 2.0g of this product and add 10ml of water to dissolve. The solution should be clarified.
take this product, precision weighing, adding water to dissolve and quantitatively dilute to make a solution containing 0.2mg per lml, as a test solution; Take the other amino benzoic acid reference substance, precision weighing, water is added to dissolve and quantitatively dilute to prepare a solution containing 1ug per 1 ml, which is used as a reference solution; 1 ml of the test solution and 9ml of the reference solution are mixed uniformly as a system applicable solution. High performance liquid chromatography (General 0512) test, using eighteen alkyl silane bonded silica gel as filler; 0.1% mol / L potassium dihydrogen phosphate solution containing 0.05 sodium heptane sulfonate (pH adjusted to 3.0 with phosphoric acid)-Methanol (68:32) as mobile phase; Detection wavelength of 279nm. Take 10ul of the applicable solution of the system and inject it into human liquid chromatograph. The number of theoretical plates shall not be less than 2000 according to the peak of p-aminobenzoic acid. The separation degree of procaine peak and p-aminobenzoic acid peak shall be greater than 2.0. 10u1 of the reference solution and the test solution were respectively injected into the liquid chromatograph, and the chromatograms were recorded. If there is a chromatographic peak in the chromatogram of the test solution that is consistent with the retention time of the p-aminobenzoic acid peak, the peak area shall be calculated according to the external standard method, and shall not exceed 0.5%.
take this product, dry to constant weight at 105°C, weight loss shall not exceed 0.5% (General rule 0831).
take l.Og of this product and check it according to law (General rule 0841). The residue left shall not exceed 0.1%.
take the residue left under the item of ignition residue, add 2ml of hydrochloric acid, steam dry on a water bath, add 4ml of dilute hydrochloric acid, dissolve at a slight temperature, add 30ml of water and 50mg of ammonium persulfate, inspection according to law (General rule 0807), compared with the standard iron solution made of 0.001% of the control solution, not deeper ().
take 2.0g of this product, add 15ml of water to dissolve, add 2ml of acetate buffer (pH 3.5) and an appropriate amount of water to make 25ml, and check according to law (General Principles 0821 first law), heavy metals should not be more than 10 parts per million.
take this product about 0.6g, precision weighing, according to the permanent stop titration method (General 0701), at 15~25°C, with sodium nitrite titration solution (0.lmol/L) titration. Each 1 ml of sodium nitrite titration solution (0.1 mol/L) corresponds to 27.28mg of C13H20N2O2 · hc1.
local anesthetic.
light shielding, sealed storage.
This product is an isotonic sterile aqueous solution containing an appropriate amount of sodium aerated procaine hydrochloride. Procaine hydrochloride (C13H20N202 • HC1) shall be included at 95.0% to 105.0% of the label load.
This product is a clear colorless liquid.
with procaine hydrochloride.
(l)2ml:40mg (2) 10ml:lOOmg (3)20ml:50mg (4)20ml:lOOmg
light shielding, closed storage.
This product is a sterile powder of procaine hydrochloride. The content of procaine hydrochloride (C13H20N202 • HCl) shall be between 95.0% and 105.0% of the labeled amount calculated as the average loading.
This product is white crystal or crystalline powder; Odorless.
take this product, according to the item of procaine hydrochloride identification (1), (3), (4) test, show the same reaction.
take the contents under the difference of loading amount, mix evenly, weigh an appropriate amount (equivalent to 0.6g of procaine hydrochloride) accurately, and follow the permanent stop titration method (General rule 0701), at 15-25 ° C, with sodium nitrite titration solution (0.lmol/L) titration. Each 1 ml of sodium nitrite titration solution (0.1 mol/L) corresponds to 27.28mg of C13H20N2O2 · hc1.
with procaine hydrochloride.
(1)0.15g (2)lg
light shielding, closed storage.